Group 1 - Regeneron Pharmaceuticals, Inc. will report its first quarter 2026 financial and operating results on April 29, 2026, before U.S. financial markets open [1] - A conference call and simultaneous webcast will be held at 8:30 AM Eastern Time on the same day [1] - Participants can access the conference call via webcast on Regeneron's website or by telephone after registering in advance [2] Group 2 - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing medicines for serious diseases [3] - The company utilizes proprietary technologies, such as VelociSuite, to enhance drug development and produce optimized fully human antibodies [4] - Regeneron aims to shape the future of medicine through data-powered insights and pioneering genetic medicine platforms [4]

Core Insights - Stran & Company, Inc. reported strong financial performance for the fiscal year ended December 31, 2025, with revenue reaching $116.2 million, a 40.6% increase from $82.7 million in 2024, driven by organic growth and new customer acquisitions [2][3][4] - The company achieved positive EBITDA of $0.2 million, a significant improvement from a loss of $3.6 million in the previous year, although it reported a net loss of $0.7 million due to increased expenses related to legal and accounting matters [2][4][11] - Stran serves over 2,000 active customers, including more than 30 Fortune 500 companies, and aims to deepen customer relationships through long-term program engagements [2][4] Financial Performance - Revenue for 2025 was $116.2 million, reflecting a 40.6% year-over-year growth, with $33.5 million increase attributed to higher spending from existing and new customers [3][4] - Gross profit rose to $34.2 million, a 32.6% increase from the prior year, with a gross margin of 29.5%, down from 31.2% due to the acquisition of the Gander Group [4][11] - Operating expenses increased by 17.8% to $36.2 million, but as a percentage of sales, they decreased to 31.1% from 37.2% in the previous year [11] Strategic Initiatives - The company is focused on enhancing its digital capabilities, including the launch of a client-branded online gifting platform to expand e-commerce offerings [2] - Stran plans to continue investing in technology, deepen enterprise customer relationships, and pursue selective acquisitions to support growth in the fragmented promotional products industry [2][4] - The strategy includes converting customers into long-term program relationships, which is expected to drive deeper engagement and more predictable revenue streams [2]

Core Viewpoint - Equillium, Inc. is advancing its investigational drug EQ504, targeting severe autoimmune and inflammatory disorders, with a Phase 1 study planned for mid-2026 and financial stability expected to support operations into 2029 [1][2]. Financial Performance - Revenue for Q4 2025 was $0, a decrease from $4.4 million in Q4 2024. For the full year 2025, no revenue was recognized compared to $41.1 million in 2024 [4]. - Research and development (R&D) expenses for Q4 2025 were $1.5 million, down from $7.3 million in Q4 2024. Total R&D expenses for 2025 were $12.8 million, significantly lower than $37.4 million in 2024 [5][6]. - General and administrative (G&A) expenses for Q4 2025 were $2.4 million, compared to $1.8 million in Q4 2024. For the full year, G&A expenses were $10.8 million, down from $11.9 million in 2024 [7]. - The net loss for Q4 2025 was $3.8 million, or $(0.04) per share, compared to a net loss of $5.8 million, or $(0.16) per share in Q4 2024. The full year net loss was $22.4 million, or $(0.39) per share, compared to $8.1 million, or $(0.23) per share in 2024 [8]. Cash Position - As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $30.3 million, an increase from $22.6 million as of December 31, 2024. The company believes this, along with a recent $35 million financing, will fund operations into 2029 [9]. Clinical Development - EQ504 is a potent and selective AhR modulator designed for targeted local delivery in gastrointestinal diseases, including ulcerative colitis, and has potential applications in inflammatory lung diseases. The Phase 1 proof-of-mechanism study is set to begin in mid-2026, with data expected approximately six months later [1][10]. - The company is also evaluating EQ302, an oral bi-specific inhibitor for gastrointestinal indications, including celiac disease [5]. Strategic Focus - The CEO emphasized that 2025 was a transformative year, with a sharpened focus on EQ504 and strengthened financial resources to support its clinical development [2]. The company aims to position EQ504 as a best-in-class oral therapy for ulcerative colitis and other inflammatory diseases [2].

Core Insights - Noodles & Company reported a 6.6% increase in comparable restaurant sales for Q4 2025 and over 9% growth in Q1 2026 to date, indicating strong momentum in sales growth [1][4][5] Financial Performance - Total revenue for Q4 2025 increased by 0.8% to $122.8 million compared to $121.8 million in Q4 2024 [5] - For the fiscal year 2025, total revenue rose by 0.4% to $495.1 million from $493.3 million in 2024 [5] - The net loss for Q4 2025 was $6.8 million, or $1.16 loss per diluted share, an improvement from a net loss of $9.7 million, or $1.70 loss per diluted share in Q4 2024 [5] - Adjusted EBITDA for Q4 2025 increased to $7.6 million from $4.0 million in the same quarter of the previous year [5][29] Operational Highlights - The company experienced a 7.3% increase in comparable sales for company-owned restaurants and a 3.8% increase for franchise restaurants in Q4 2025 [5][27] - The restaurant contribution margin improved to 14.1% in Q4 2025 from 11.2% in Q4 2024, reflecting enhanced operational efficiency [5][40] - The company closed 33 underperforming restaurants in 2025, which contributed to a material transfer of sales to nearby locations [4][5] Business Outlook - The company anticipates significant further growth in Adjusted EBITDA for 2026, supported by the strong sales acceleration observed in early 2026 [6][11] - Expectations for fiscal year 2026 include total revenue between $478 million to $493 million, with comparable restaurant sales growth projected at 6.0% to 9.0% [11][12] Liquidity Position - As of December 30, 2025, the company had cash and cash equivalents of $1.3 million and outstanding debt of $110.2 million [6]

Core Viewpoint - LEEF Brands, Inc. reported significant financial improvements in Q4 2025 and full-year 2025, highlighting a transition to a more efficient operational model and increased profitability due to vertical integration and expansion efforts [4][6]. Fourth Quarter 2025 Highlights - Revenue reached $8.3 million, a 38.9% increase year-over-year - Gross profit was $3.8 million, up 188.2% year-over-year - Gross margin improved to 45.5%, an increase of 23.5 percentage points year-over-year - Adjusted EBITDA was $1.0 million, compared to a loss of $3.1 million in Q4 2024, marking a 131.9% improvement year-over-year - Free cash flow was $1.2 million, compared to a negative $1.6 million in Q4 2024, an improvement of 173.4% year-over-year [8]. Full-Year 2025 and Second Half 2025 Highlights - Total revenue for 2025 was $34.8 million, a 22.1% increase year-over-year, with H2 revenue at $16.7 million, down 7.7% compared to H1 2025 - Gross profit for the year was $10.5 million, up 36.5% year-over-year, with H2 gross profit at $6.9 million, a 94.2% increase compared to H1 2025 - Full-year gross margin was 30.1%, up 3.2 percentage points year-over-year, with H2 gross margin at 41.4%, an increase of 21.7 percentage points compared to H1 2025 - Adjusted EBITDA for FY 2025 was $(0.4) million, an improvement from $(2.4) million in FY 2024, with H2 adjusted EBITDA at $1.7 million, compared to $(2.2) million in H1 2025, marking a 179.6% improvement - Free cash flow for FY 2025 was $(1.1) million, an improvement from $(7.3) million in FY 2024, with H2 free cash flow at $1.3 million, compared to $(2.4) million in H1 2025, a 155.0% improvement [8][10]. Operational Efficiency and Expansion - LEEF cultivated nearly 2 million plants at Salisbury Canyon Ranch, significantly reducing biomass production costs to approximately $8 per pound, compared to $20–$50 per pound when sourced externally, creating a structural cost advantage [5]. - The company announced a $4.5 million initial closing of a financing round led by Mindset Capital to support the expansion of Salisbury Canyon Ranch, which is expected to enhance margins and drive long-term value creation [6][7][8]. Future Outlook - The company anticipates a temporary margin decline in Q2 2026 due to reliance on third-party sourcing during harvest transitions, followed by improved performance in H2 2026 as additional cultivation comes online - As Salisbury Canyon Ranch approaches full buildout, the company expects to achieve greater stability in margins and cash flow over time [9][10].

Core Insights - Celcuity Inc. is positioned for a transformative year in 2026, with anticipated topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study, which could enhance treatment standards for HR+/HER2- advanced breast cancer patients [2] - The FDA has accepted Celcuity's New Drug Application for gedatolisib, granting Priority Review with a PDUFA goal date of July 17, 2026 [4] Business Highlights - The Phase 3 VIKTORIA-1 study has shown promising results, with a median progression-free survival of 16.6 months for the gedatolisib triplet compared to 1.9 months for fulvestrant, indicating a significant improvement in patient outcomes [5] - The gedatolisib triplet demonstrated a median time to definitive deterioration of 23.7 months, significantly better than the 4.0 months for fulvestrant [5] - The triplet therapy was generally well tolerated, with low-grade treatment-related adverse events reported [5] Financial Results - Total operating expenses for Q4 2025 were $49.2 million, up from $36.4 million in Q4 2024, while full-year operating expenses reached $172.2 million compared to $113.3 million in 2024 [7] - Research and development expenses for Q4 2025 were $37.6 million, an increase from $33.5 million in the prior year, driven by higher employee and consulting costs [8] - The net loss for Q4 2025 was $51.0 million, or $0.97 per share, compared to a net loss of $36.7 million, or $0.85 per share, in Q4 2024 [12] Cash Position - Cash, cash equivalents, and short-term investments totaled $441.5 million at the end of 2025, expected to finance operations through 2027 [14]

Core Viewpoint - Colliers International Group Inc. has successfully completed a private placement of C$550 million (approximately US$400 million) in fixed-rate senior unsecured notes due 2033, aimed at strengthening its balance sheet and enhancing financial flexibility [1][4]. Group 1: Financial Details - The private placement consists of 4.73% fixed-rate senior unsecured notes issued by Colliers Macaulay Nicolls Inc., a subsidiary of Colliers, and fully guaranteed by Colliers [2]. - The payment obligations under the notes rank equally with all other unsecured and unsubordinated indebtedness of the issuer and Colliers, including the senior unsecured revolving credit facility and existing senior unsecured notes [2]. Group 2: Use of Proceeds - Colliers intends to utilize the proceeds from the notes for general corporate purposes, specifically for repaying outstanding borrowings under its revolving credit facility [3]. Group 3: Management Commentary - The Vice President of Finance & Treasurer stated that this financing will further strengthen the company's balance sheet and enhance financial flexibility while executing its long-term growth strategy. The strong support from institutional investors reflects confidence in the company's performance and disciplined capital management approach [4]. Group 4: Company Overview - Colliers is a global diversified professional services and investment management company with over 30 years of consistent growth, generating $5.6 billion in annual revenues and managing $108 billion in assets [7].

Core Insights - Nkarta, Inc. is focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases and reported its financial results for Q4 and the full year 2025 [1][2] Financial Highlights - The company had a cash balance of $295.1 million as of December 31, 2025, which is projected to fund operations into 2029 [6][7] - Research and development (R&D) expenses for the full year 2025 were $90.4 million, with Q4 expenses at $25.3 million [7] - General and administrative (G&A) expenses totaled $31.6 million for the full year 2025, with $5.7 million in Q4 [7] - The net loss for the full year 2025 was $104.1 million, or $1.41 per share, while the Q4 net loss was $27.4 million, or $0.37 per share [7][17] Clinical Program Updates - Nkarta is advancing its CAR-NK cell therapy platform, with dose escalation now at 4 billion cells per dose in a three-dose cycle, totaling 12 billion cells [2][6] - The Ntrust-1 and Ntrust-2 clinical trials are ongoing, evaluating NKX019 in multiple autoimmune diseases, with initial clinical data expected to be presented at a medical conference in 2026 [6][7] - The trials are designed to assess the safety and efficacy of NKX019, leveraging a unique approach that does not involve supplemental cytokines or antibody-based therapeutics [9][10] Strategic Focus - The company has onboarded a clinical team with expertise in autoimmune diseases and has adjusted its workforce to manage investor capital responsibly [2] - Nkarta aims to maximize the depth and durability of B-cell depletion and clinical response through its NKX019 therapy [2][8]

Core Viewpoint - Great Pacific Gold Corp. has announced a public offering of up to 32,000,000 units at a price of $0.47 per unit, aiming for gross proceeds of up to $15,040,000 to advance its gold-copper projects in Papua New Guinea [1][5]. Offering Details - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at $0.70 for 24 months post-offering [2]. - The offering will be conducted under a prospectus supplement to the base shelf prospectus dated March 19, 2026, and will be available in Canada (excluding Quebec) and potentially through private placements in the U.S. and offshore [3]. - An over-allotment option allows agents to purchase an additional 15% of the units at the offering price, exercisable up to 48 hours before closing [4]. Use of Proceeds - Net proceeds from the offering will be allocated to advancing the company's gold-copper projects in Papua New Guinea, along with general working capital and corporate purposes [5]. Closing Timeline - The offering is expected to close around April 2, 2026, subject to conditions including approval from the TSX Venture Exchange [5]. Company Overview - Great Pacific Gold aims to be a leading gold-copper development company in Papua New Guinea, with a portfolio of exploration-stage projects [8]. - The company's flagship project, the Wild Dog Project, features significant geological targets and has yielded high-grade drilling results [12]. - Other notable projects include the Kesar Project and the Arau Project, both of which have shown promising exploration results and high-grade gold presence [12].

Core Insights - E-Power Inc. has achieved a significant milestone in its global expansion strategy with a successful site inspection of the ATSC SOLARTECH facility in Vietnam, aligning with its "Closed-Loop" industrial ecosystem to serve the growing AI Data Center and energy storage markets [1][2] Strategic Collaboration and Global Supply Chain Resilience - E-Power's leadership team engaged in discussions with ATSC SOLARTECH's executives, reaching a preliminary consensus on a "Small Asset, Large Trade" cooperation model [2] Vietnam Expansion Highlights - The Vietnam project will integrate E-Power's top-tier anode technology with ATSC SOLARTECH's specialized infrastructure, enhancing production capabilities [4] - E-Power's Chairman emphasized that the move into Vietnam is a natural extension of the industrial chain, leveraging over 100 patents in anode materials and a specialized microgrid task force [5] Next Steps - E-Power plans to finalize the "Minimum Capacity Plan" by the end of March 2026, followed by the registration of the Vietnam subsidiary and customer certification processes [6] Production and Compliance Advantages - The Vietnam-based production will utilize local origin certification to meet U.S. export requirements, aiming for a local value-added threshold of 30% to access potential U.S. subsidies [8] - The Hung Yen industrial zone offers robust infrastructure and competitive labor costs, with local manufacturing efficiency at approximately 70% of domestic Chinese standards [8] - Existing customers like Envision, Sunwoda, and Gotion have established a presence in Vietnam, facilitating streamlined certification and enhanced supply chain responsiveness [8] Advanced Material and Microgrid Synergy - E-Power plans to pilot its minimum viable capacity for anode materials in Vietnam, with future potential for advanced Silicon-Carbon anodes [8] - The expansion supports E-Power's mission to provide integrated microgrid solutions, serving as a strategic base for deploying microgrid automation across Southeast Asia and North America [8]